I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| epithelial cell of proximal tubule | 9 studies | 52% ± 22% | |
| epithelial cell | 4 studies | 48% ± 31% | |
| hepatocyte | 4 studies | 41% ± 18% | |
| parietal epithelial cell | 3 studies | 46% ± 2% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| epithelial cell of proximal tubule | 9 studies | 52% ± 22% | |
| epithelial cell | 4 studies | 48% ± 31% | |
| hepatocyte | 4 studies | 41% ± 18% | |
| parietal epithelial cell | 3 studies | 46% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 100% | 13343.09 | 89 / 89 | 89% | 310.89 | 804 / 901 |
| liver | 100% | 11671.00 | 226 / 226 | 86% | 299.97 | 348 / 406 |
| pancreas | 100% | 396.70 | 328 / 328 | 19% | 13.41 | 34 / 178 |
| ovary | 9% | 5.43 | 16 / 180 | 68% | 42.93 | 292 / 430 |
| intestine | 45% | 202.11 | 436 / 966 | 9% | 6.00 | 49 / 527 |
| bladder | 33% | 22.67 | 7 / 21 | 9% | 5.39 | 46 / 504 |
| skin | 26% | 11.05 | 474 / 1809 | 13% | 4.23 | 62 / 472 |
| uterus | 25% | 57.42 | 42 / 170 | 9% | 7.10 | 43 / 459 |
| breast | 32% | 23.23 | 146 / 459 | 1% | 0.44 | 8 / 1118 |
| lung | 16% | 6.45 | 94 / 578 | 3% | 1.67 | 34 / 1155 |
| peripheral blood | 12% | 11.79 | 108 / 929 | 0% | 0 | 0 / 0 |
| prostate | 11% | 4.78 | 28 / 245 | 0% | 0 | 0 / 502 |
| stomach | 4% | 1.28 | 13 / 359 | 6% | 5.70 | 18 / 286 |
| esophagus | 2% | 1.06 | 26 / 1445 | 2% | 1.16 | 4 / 183 |
| thymus | 2% | 0.54 | 10 / 653 | 1% | 0.31 | 7 / 605 |
| adipose | 2% | 2.63 | 30 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 1% | 8.54 | 2 / 241 | 0% | 0 | 0 / 0 |
| adrenal gland | 1% | 0.26 | 2 / 258 | 0% | 0 | 0 / 230 |
| blood vessel | 1% | 0.32 | 8 / 1335 | 0% | 0 | 0 / 0 |
| brain | 0% | 0.10 | 7 / 2642 | 0% | 0.04 | 1 / 705 |
| heart | 0% | 0.47 | 2 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006805 | Biological process | xenobiotic metabolic process |
| GO_0006629 | Biological process | lipid metabolic process |
| GO_0008209 | Biological process | androgen metabolic process |
| GO_0052695 | Biological process | cellular glucuronidation |
| GO_0008210 | Biological process | estrogen metabolic process |
| GO_0016020 | Cellular component | membrane |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0015020 | Molecular function | glucuronosyltransferase activity |
| GO_0001972 | Molecular function | retinoic acid binding |
| Gene name | UGT2B7 |
| Protein name | UDP-glucuronosyltransferase 2B7 (UDPGT 2B7) (UGT2B7) (EC 2.4.1.17) (3,4-catechol estrogen-specific UDPGT) (UDP-glucuronosyltransferase 2B9) (UDPGT 2B9) (UDPGTh-2) glucuronosyltransferase (EC 2.4.1.17) UDP-glucuronosyltransferase (EC 2.4.1.17) |
| Synonyms | UGTB2B9 |
| Description | FUNCTION: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile . Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds . Catalyzes the glucuronidation of endogenous steroid hormones such as androgens (epitestosterone, androsterone) and estrogens (estradiol, epiestradiol, estriol, catechol estrogens) . Also regulates the levels of retinoic acid, a major metabolite of vitamin A involved in apoptosis, cellular growth and differentiation, and embryonic development . Contributes to bile acid (BA) detoxification by catalyzing the glucuronidation of BA substrates, which are natural detergents for dietary lipids absorption . Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist losartan, caderastan and zolarsatan, drugs which can inhibit the effect of angiotensin II . Also metabolizes mycophenolate, an immunosuppressive agent . . |
| Accessions | P16662 Q9HCT7 A0A087X084 Q5QKR3 ENST00000508661.5 Q99912 D6RH08 ENST00000502942.5 E9PBP8 ENST00000305231.12 ENST00000622664.1 |
